Jens H Kuhn

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Clarification and guidance on the proper usage of virus and virus species names
    Jens H Kuhn
    Integrated Research Facility at Fort Detrick IRF Frederick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, B 8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA
    Arch Virol 155:445-53. 2010
  2. ncbi Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae
    Jens H Kuhn
    Integrated Research Facility at Fort Detrick IRF Frederick, Division of Clinical Research DCR, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, B 8200 Research Plaza, Fort Detrick, Frederick, MD, 21702, USA
    Arch Virol 158:301-11. 2013
  3. ncbi The International Code of Virus Classification and Nomenclature (ICVCN): proposal to delete Rule 3.41
    Jens H Kuhn
    Integrated Research Facility at Fort Detrick IRF Frederick, Division of Clinical Research DCR, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Fort Detrick, Frederick, MD, USA
    Arch Virol 158:297-9. 2013
  4. ncbi Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain
    Wu Ou
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Bldg, 29B, Room 5NN22, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Virol J 9:32. 2012
  5. ncbi Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations
    Jens H Kuhn
    Integrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, National Interagency Biodefense Campus, B 8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA
    Arch Virol 155:2083-103. 2010
  6. ncbi Evaluation of perceived threat differences posed by filovirus variants
    Jens H Kuhn
    National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of Clinical Research, Integrated Research Facility at Fort Detrick, Frederick, Maryland, USA
    Biosecur Bioterror 9:361-71. 2011
  7. ncbi Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry
    Sheli R Radoshitzky
    U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702, USA
    J Virol 85:8502-13. 2011
  8. ncbi Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses
    Sheli R Radoshitzky
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA
    Expert Opin Drug Discov 7:613-32. 2012
  9. ncbi Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins
    Wu Ou
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA, Bethesda, MD, USA
    J Virol Methods 174:99-109. 2011
  10. ncbi Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies
    Maryam Keshtkar-Jahromi
    Union Memorial Hospital, University of Maryland, Baltimore, MD, USA
    Antiviral Res 90:85-92. 2011

Collaborators

Detail Information

Publications13

  1. ncbi Clarification and guidance on the proper usage of virus and virus species names
    Jens H Kuhn
    Integrated Research Facility at Fort Detrick IRF Frederick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, B 8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA
    Arch Virol 155:445-53. 2010
    ....
  2. ncbi Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae
    Jens H Kuhn
    Integrated Research Facility at Fort Detrick IRF Frederick, Division of Clinical Research DCR, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, B 8200 Research Plaza, Fort Detrick, Frederick, MD, 21702, USA
    Arch Virol 158:301-11. 2013
    ..Most importantly, it would counter the increasing confusion in genetic variant naming due to the identification of ever more sequences through technological breakthroughs in high-throughput sequencing and environmental sampling...
  3. ncbi The International Code of Virus Classification and Nomenclature (ICVCN): proposal to delete Rule 3.41
    Jens H Kuhn
    Integrated Research Facility at Fort Detrick IRF Frederick, Division of Clinical Research DCR, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Fort Detrick, Frederick, MD, USA
    Arch Virol 158:297-9. 2013
    ..It is proposed to delete Rule 3.41 of the International Code of Virus Classification and Nomenclature, which requires the name of a virus taxon to precede the term for the taxonomic unit...
  4. ncbi Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain
    Wu Ou
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Bldg, 29B, Room 5NN22, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Virol J 9:32. 2012
    ..We hypothesized that immunization with MLD-deleted GP1,2 (GPΔMLD) would induce cross-species immunity by making more conserved regions accessible to the immune system...
  5. ncbi Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations
    Jens H Kuhn
    Integrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, National Interagency Biodefense Campus, B 8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA
    Arch Virol 155:2083-103. 2010
    ..Furthermore, we explain the etymological derivation of individual names, their pronunciation, and their correct use, and we elaborate on demarcation criteria for each taxon and virus...
  6. ncbi Evaluation of perceived threat differences posed by filovirus variants
    Jens H Kuhn
    National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of Clinical Research, Integrated Research Facility at Fort Detrick, Frederick, Maryland, USA
    Biosecur Bioterror 9:361-71. 2011
    ....
  7. ncbi Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry
    Sheli R Radoshitzky
    U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702, USA
    J Virol 85:8502-13. 2011
    ..They join cathepsins and integrins as novel modulators of filovirus cell entry, might play important roles in pathogenesis, and could be exploited for the synthesis of powerful new antivirals...
  8. ncbi Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses
    Sheli R Radoshitzky
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA
    Expert Opin Drug Discov 7:613-32. 2012
    ....
  9. ncbi Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins
    Wu Ou
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA, Bethesda, MD, USA
    J Virol Methods 174:99-109. 2011
    ..Together, our results suggest that this panel of antibodies may prove useful for both in vitro analyses of ebolavirus GP₁,₂, as well as analysis of clinically relevant samples...
  10. ncbi Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies
    Maryam Keshtkar-Jahromi
    Union Memorial Hospital, University of Maryland, Baltimore, MD, USA
    Antiviral Res 90:85-92. 2011
    ..CCHF-immunoglobulin is also in use, but without clear evidence of efficacy. In this article, we review the development of prophylaxis and therapy for CCHF and discuss future prospects for vaccine and drug development...
  11. ncbi Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses
    Thomas Hoenen
    Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA Department of Virology, Philipps University Marburg, Marburg, Germany
    Antiviral Res 91:195-208. 2011
    ....
  12. ncbi Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression
    Victoria Wahl-Jensen
    Integrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, United States of America
    PLoS Negl Trop Dis 5:e1359. 2011
    ..In contrast, VLP(VP40) (particles lacking GP(1,2)) caused an aberrant response. This suggests that GP(1,2) binding to macrophages plays an important role in the immediate cellular response...
  13. ncbi Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin
    Sheli R Radoshitzky
    U S Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Fort Detrick, Frederick, MD 21702, USA
    J Virol 84:10569-80. 2010
    ..Our results demonstrate that BST-2 might be a broad antiviral factor with the ability to restrict release of a wide variety of human pathogens. However, at least filoviruses, RVFV, and CPXV are immune to its inhibitory effect...